AbbVie Inc. (ABBV)
| Market Cap | 449.37B +33.0% |
| Revenue (ttm) | 64.39B +10.4% |
| Net Income | 6.27B +67.7% |
| EPS | 3.54 +68.5% |
| Shares Out | 1.77B |
| PE Ratio | 126.80 |
| Forward PE | 16.83 |
| Dividend | $6.92 (2.72%) |
| Ex-Dividend Date | Jul 15, 2026 |
| Volume | 2,208,355 |
| Open | 252.54 |
| Previous Close | 257.41 |
| Day's Range | 247.00 - 255.52 |
| 52-Week Range | 187.62 - 267.47 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 268.68 (+5.64%) |
| Earnings Date | Jul 31, 2026 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial StatementsAnalyst Summary
According to 31 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $268.68, which is an increase of 5.64% from the latest price.
News
AbbVie says ‘quite pleased’ with Skyrizi momentum
Says “very excited” about oncology portfolio.
AbbVie raises FY26 revenue view to about $67.6B from about $67.3B
FY26 consensus $67.27B.
AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84
Sees Q3 revenue about $17.2B, consensus $17.3B.
AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’
Sees FY26 adjusted operating margin approaching 47% of sales. Sees FY26 tax rate 14.5%.
AbbVie says continues to make ‘excellent progress’ advancing pipeline
Says immunology pipeline a “major growth driver” long term. Says long term outlook remains “very strong.” Comments taken from Q2 earnings conference call.
AbbVie Earnings Call Transcript: Q2 2026
Second quarter results exceeded expectations with double-digit revenue growth and raised full-year guidance. Immunology and neuroscience segments drove performance, while the Apogee acquisition and new product approvals strengthen the long-term outlook.
AbbVie Earnings release: Q2 2026
AbbVie released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps
AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.
AbbVie cuts its full-year guidance to account for its pending acquisition of Apogee Therapeutics.
AbbVie reports Q2 adjusted EPS $3.65, consensus $3.61
Reports Q2 revenue $16.99, consensus $16.76B. “AbbVie (ABBV) delivered another excellent quarter, marked by outstanding execution and pipeline advancement. We also announced the proposed acquisition o...
AbbVie cuts FY26 adjusted EPS view to $13.87-$14.07 from $13.91-$14.11
FY26 consensus $14.12. “AbbVie (ABBV) is updating its adjusted diluted EPS guidance to include the impact of the proposed Apogee Therapeutics acquisition, which is expected to be $0.14 dilutive in…
AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates
AbbVie trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping second-quarter estimates on strong immunology drug sales.
AbbVie Reports Second-Quarter 2026 Financial Results
Reports Second-Quarter Diluted EPS of $2.03 on a GAAP Basis, an Increase of 290.4 Percent; Adjusted Diluted EPS of $3.65, an Increase of 22.9 Percent; These Results Include an Unfavorable Impact of $0...
JUVÉDERM® Day Returns to U.S. on August 19
Allergan Aesthetics celebrates fourth annual JUVÉDERM ® Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first U.S. F...
AbbVie announces Elahere availability in Singapore
AbbVie (ABBV) announced availability of Elahere in Singapore for the treatment of Platinum-Resistant Ovarian Cancer. Elahere is the first and only antibody-drug conjugate therapy approved specifically...
AbbVie announces European Commission approval for Rinvoq
AbbVie (ABBV) announced that the European Commission has approved Rinvoq for the treatment of adult and adolescent patients 12 years and older with severe alopecia areata. “The European Commission’s a...
AbbVie price target raised to $300 from $275 at Barclays
Barclays raised the firm’s price target on AbbVie (ABBV) to $300 from $275 and keeps an Overweight rating on the shares. The firm adjusted targets in the biopharmaceuticals space as…
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
RINVOQ ® is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA) Approval was based on the pivotal Phase 3 UP-AA clinical program, whi...
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phas...
Genmab, AbbVie provide clarification on Phase 3 EPCORE(R) DLBCL-1 trial
Genmab A/S (GMAB) and AbbVie (ABBV) provided clarification on the primary endpoints from the Phase 3 EPCORE(R) DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody(R)-CD3xCD20), a T-cell engaging...
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 stu...
AbbVie price target raised to $282 from $273 at Canaccord
Canaccord raised the firm’s price target on AbbVie (ABBV) to $282 from $273 and keeps a Buy rating on the shares. The firm updated its model ahead of Q2 results…
AbbVie’s Allergan Aesthetics receives approval for Boey in Europe
Allergan Aesthetics announced the European Commission has approved Boey in Europe, for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frow...
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹ Results may ...
AbbVie price target raised to $260 from $230 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on AbbVie (ABBV) to $260 from $230 and keeps a Neutral rating on the shares. The firm adjusted targets in the…